低剂量苯巴比妥对肝微粒体酶诱导三个指标的影响
The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction.
作者信息
Price D E, Mehta A, Park B K, Hay A, Feely M P
出版信息
Br J Clin Pharmacol. 1986 Dec;22(6):744-7. doi: 10.1111/j.1365-2125.1986.tb02970.x.
Abstract
The effects of low-dose phenobarbitone on three indices of hepatic enzyme induction were studied. Eight healthy volunteers took phenobarbitone 7.5 mg daily for 4 weeks followed by 15 mg daily for 4 weeks; five subjects took 30 mg daily for a further 2 weeks. Phenobarbitone 15 mg daily produced a significant rise in antipyrine clearance (P less than 0.05). Phenobarbitone 30 mg daily produced a further rise, but probably because of the reduced numbers of subjects, this did not achieve significance (P = 0.06). Urinary 6-beta-hydroxycortisol and D-glucaric acid levels did not change significantly and remained within the range seen in subjects not taking enzyme-inducing drugs. We conclude that phenobarbitone 7.5 mg daily produces little (if any) enzyme induction whereas 15 mg, or more, may have the potential to produce drug interactions through enzyme induction.
摘要
研究了低剂量苯巴比妥对肝酶诱导三个指标的影响。八名健康志愿者连续4周每天服用7.5毫克苯巴比妥，随后4周每天服用15毫克；另外五名受试者连续2周每天服用30毫克。每天服用15毫克苯巴比妥使安替比林清除率显著升高（P<0.05）。每天服用30毫克苯巴比妥使清除率进一步升高，但可能由于受试者数量减少，未达到显著水平（P = 0.06）。尿中6-β-羟基皮质醇和D-葡萄糖醛酸水平无显著变化，仍在未服用酶诱导药物的受试者所见范围内。我们得出结论，每天服用7.5毫克苯巴比妥几乎不产生（如果有）酶诱导作用，而15毫克或更多剂量可能有通过酶诱导产生药物相互作用的潜力。
相似文献
1
The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction.低剂量苯巴比妥对肝微粒体酶诱导三个指标的影响
Br J Clin Pharmacol. 1986 Dec;22(6):744-7. doi: 10.1111/j.1365-2125.1986.tb02970.x.
2
Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.测定尿中6-β-羟基皮质醇排泄量作为体内参数，用于临床评估安替比林、苯巴比妥和利福平的微粒体酶诱导能力。
Eur J Clin Pharmacol. 1979 Mar 26;15(2):139-45. doi: 10.1007/BF00609878.
3
Enzyme induction by phenobarbitone and vitamin K1 disposition in man.苯巴比妥对酶的诱导作用及人体中维生素K1的代谢处置
Br J Clin Pharmacol. 1984 Jul;18(1):94-7. doi: 10.1111/j.1365-2125.1984.tb05028.x.
4
Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man.酶诱导药物组合及其对人体肝脏微粒体酶活性的影响。
Eur J Clin Pharmacol. 1983;24(2):247-50. doi: 10.1007/BF00613826.
5
Effect of phenobarbitone on hepatic drug-metabolizing enzymes and urinary D-glucaric acid excretion in man.苯巴比妥对人体肝脏药物代谢酶及尿中D-葡萄糖醛酸排泄的影响。
Br J Clin Pharmacol. 1975 Jun;2(3):257-62. doi: 10.1111/j.1365-2125.1975.tb01584.x.
6
Phenobarbitone-induced urinary excretions of D-glucaric acid and 6beta-hydroxycortisol in man.
Can J Physiol Pharmacol. 1976 Oct;54(5):778-82. doi: 10.1139/y76-108.
7
Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin.使用安替比林、苯巴比妥和利福平进行酶诱导对血浆脂质的影响。
Clin Pharmacol Ther. 1979 May;25(5 Pt 1):591-7. doi: 10.1002/cpt1979255part1591.
8
Enzyme induction and renal function in man.人体中的酶诱导作用与肾功能
Br J Clin Pharmacol. 1977 Feb;4(1):33-7. doi: 10.1111/j.1365-2125.1977.tb00663.x.
9
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.抗惊厥药物对癫痫患者相对酶诱导特性的比较研究。
Br J Clin Pharmacol. 1984 Sep;18(3):401-10. doi: 10.1111/j.1365-2125.1984.tb02482.x.
10
The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man.肝脏微粒体酶诱导剂和抑制剂对人体胰岛素介导的葡萄糖代谢的影响。
Br J Clin Pharmacol. 1986 Jan;21(1):19-26. doi: 10.1111/j.1365-2125.1986.tb02818.x.
引用本文的文献
1
Antenatal phenobarbital for reducing neonatal jaundice after red cell isoimmunization.产前使用苯巴比妥降低红细胞同种免疫后的新生儿黄疸。
Cochrane Database Syst Rev. 2007 Apr 18;2007(2):CD005541. doi: 10.1002/14651858.CD005541.pub2.
2
Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.尿6β-羟基皮质醇：一种用于评估人类和动物中通过CYP3A介导的药物诱导或药物抑制作用的有效检测方法。
Eur J Clin Pharmacol. 2003 Dec;59(10):713-33. doi: 10.1007/s00228-003-0690-3. Epub 2003 Nov 6.
3
Compliance with oral corticosteroids during steroid trials in chronic airways obstruction.慢性气道阻塞患者进行类固醇试验期间口服皮质类固醇的依从性。
Thorax. 1996 Mar;51(3):323-4. doi: 10.1136/thx.51.3.323.
4
Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts.英国药理学会临床药理学分会会议记录。爱尔兰，1988年7月6日至8日。摘要。
Br J Clin Pharmacol. 1988 Nov;26(5):615P-678P.
5
Measuring treatment compliance of men with non-gonococcal urethritis receiving oxytetracycline combined with low dose phenobarbitone.测量接受土霉素联合低剂量苯巴比妥治疗的非淋菌性尿道炎男性患者的治疗依从性。
Genitourin Med. 1988 Oct;64(5):312-5. doi: 10.1136/sti.64.5.312.
6
Use of a pharmacological indicator to monitor compliance with thyroxine.使用药理学指标监测甲状腺素的依从性。
Eur J Clin Pharmacol. 1988;35(3):327-9. doi: 10.1007/BF00558274.
7
Low-dose phenobarbitone as an indicator of compliance with drug therapy.低剂量苯巴比妥作为药物治疗依从性的指标。
Br J Clin Pharmacol. 1987 Jul;24(1):77-83. doi: 10.1111/j.1365-2125.1987.tb03139.x.
8
A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteers.比较短半衰期标志物（低剂量异烟肼）、长半衰期药理学指标（低剂量苯巴比妥）以及控释“治疗药物”（美托洛尔，倍他乐克）的测量结果在反映志愿者不完全依从性方面的情况。
Br J Clin Pharmacol. 1990 Sep;30(3):437-41. doi: 10.1111/j.1365-2125.1990.tb03795.x.
9
Pharmacokinetics of phenobarbital in the cat following multiple oral administration.多次口服给药后苯巴比妥在猫体内的药代动力学
Can J Vet Res. 1990 Jun;54(3):309-12.
10
The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance.预测稳态血浆苯巴比妥浓度（低剂量苯巴比妥用药后），以优化其作为依从性指标的应用。
Br J Clin Pharmacol. 1991 Sep;32(3):329-33. doi: 10.1111/j.1365-2125.1991.tb03907.x.
本文引用的文献
1
Analysis of barbiturates in blood by high-performance liquid chromatography.高效液相色谱法分析血液中的巴比妥类药物。
J Chromatogr. 1981 Nov 13;226(1):117-23. doi: 10.1016/s0378-4347(00)84212-7.
2
Phenobarbital in the monitoring of compliance.用于监测依从性的苯巴比妥。
Ann Intern Med. 1984 Jul;101(1):138-9. doi: 10.7326/0003-4819-101-1-138_2.
3
Effect of low-dose phenobarbital on hepatic microsomal UDP-glucuronyl transferase activity.低剂量苯巴比妥对肝微粒体UDP-葡萄糖醛酸转移酶活性的影响。
Biochem Pharmacol. 1983 Jul 15;32(14):2143-7. doi: 10.1016/0006-2952(83)90219-8.
4
Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects.低剂量苯巴比妥对正常受试者肝脏微粒体酶诱导及血浆脂蛋白五个间接指标的影响。
Br J Clin Pharmacol. 1981 Oct;12(4):592-6. doi: 10.1111/j.1365-2125.1981.tb01274.x.
5
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.苯巴比妥诱导人体血浆安替比林半衰期缩短的遗传控制。
J Clin Invest. 1969 Dec;48(12):2202-9. doi: 10.1172/JCI106186.
6
Urinary D-glucaric acid assay by an improved enzymatic procedure.采用改进的酶法测定尿中D-葡糖二酸
Clin Chim Acta. 1974 Feb 28;51(1):47-51. doi: 10.1016/0009-8981(74)90060-6.
7
Dose-dependent enzyme induction.
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):514-20. doi: 10.1002/cpt1973144part1514.
8
A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine.人尿中6β-羟基皮质醇的直接放射免疫测定法。
J Steroid Biochem. 1978 Oct;9(10):963-6. doi: 10.1016/0022-4731(78)90058-4.
9
Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.
Pharmacology. 1979;18(4):210-23. doi: 10.1159/000137254.
10
Clinical implications of enzyme induction.酶诱导的临床意义。
Basic Life Sci. 1975;6:273-301. doi: 10.1007/978-1-4615-8954-9_9.
Zotero 插件